HBeAg-negative/ HBeAg-positive / anti-HBeAg/ HBeAg Seroconversion

Tenofovir (Viread) Produces Continued HBV Suppression through 96 Weeks in HBeAg Positive and Negative Patients: Studies 102 and 103 - 11/05/2008

Long-term Entecavir (Baraclude) Reverses Liver Fibrosis in HBeAg Positive and HBeAg Negative Chronic Hepatitis B Patients - 11/05/2008

Long-term Efficacy and Safety of Adefovir (Hepsera) for the Treatment of Chronic Hepatitis B in HBeAg Positive Patients - 10/03/08

Sustained HBeAg and HBsAg Loss in Chronic Hepatitis B Patients Treated with Pegylated Interferon - 9/25/08

High Pre-treatment ALT Levels May Predict Earlier HBeAg Seroconversion in Chronic Hepatitis B Patients Treated with Lamivudine (Epivir-HBV) - 9/16/08

Entecavir (Baraclude) Produces Greater Decrease in HBV DNA than Adefovir (Hepsera) in Treatment-naive HBeAg+ Patients: 96 Week Data from EARLY Study - 5/06/08

HBeAg and HBV DNA Predict Outcomes of Pegylated Interferon Therapy for Chronic Hepatitis B - 2/19/08

Disease Progression in Patients with HBeAg-negative Chronic Hepatitis B - 1/29/08

Extended Duration Pegylated Interferon Alfa-2a (Pegasys) for Patients with HBeAg Negative Chronic Hepatitis B - 1/11/08

Hepatitis Reactivation Following HBeAg Seroconversion - 12/14/07

Individuals with Hepatitis B Virus Genotype C Experience HBeAg Clearance Later and Less Often - 12/14/07

Gender Difference in the Natural Course of HBeAg-Positive Chronic Hepatitis B - 11/13/07

Entecavir Produces Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in HBeAg-positive Patients - 5/25/07

Lamivudine/Adefovir Significantly Reduces the Development and Progression of Esophageal Varices in HBeAg-negative Patients with Cirrhosis  - 4/17/07

Sustained HBeAg Response Occurs with Both Telbivudine and Lamivudine  - 4/13/07